about intercept  intercept pharmaceuticals inc careers partnering toggle navigation about about intercept leadership board of directors contact us rd fxr therapeutic focus pbc nash psc alcoholic hepatitis pipeline expanded access discovery compounds scientific presentations patient resources pbc disease information pbc patient stories investors  media press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage investor faqs contact us about  about intercept leadership board of directors contact us rd  fxr therapeutic areas primary biliary cirrhosis nash portal hypertensioncirrhosis bile acid diarrhea pipeline discovery compounds publications and conference materials patient resources  primary biliary cirrhosis nash investors  press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage ownership profile investor faqs contact us  home  about intercept learn about clinical trials that are currently recruiting — phase  nash study— phase  pbc study— phase  psc study— phase  biliary atresia study we see you at intercept our work is motivated by our desire to help patients and families who struggle with chronic liver diseases and need better treatment options about intercept intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive nonviral liver diseases intercept’s lead product ocaliva® obeticholic acid was granted accelerated approval by us food and drug administration fda in may of  for the treatment of primary biliary cholangitis previously known as primary biliary cirrhosis pbc in combination with ursodeoxycholic acid udca in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca ocaliva is the first pbc therapy that targets the farnesoid x receptor fxr a key regulator of bile acid inflammatory fibrotic and metabolic pathways for more information please visit ocalivacom obeticholic acid oca is also being evaluated for potential indications across a variety of additional chronic liver diseases including nonalcoholic steatohepatitis nash primary sclerosing cholangitis psc and biliary atresia the fda has granted oca breakthrough therapy designation for the treatment of nash with liver fibrosis intercept owns worldwide rights to oca outside of japan china and korea where it has outlicensed the product candidate to sumitomo dainippon pharma founded in  in new york new york intercept now has operations in the united states europe canada and australia ocaliva is a registered trademark of intercept pharmaceuticals inc leadership find out more about our outstanding leadership board of directors learn more about our industryleading board of directors contact us contact intercept for job media investor or partnering inquiries about intercept leadership board of directors contact us rd fxr therapeutic focus pbc nash psc investigator initiated research pipeline expanded access discovery compounds scientific presentations patient resources pbc disease information pbc patient stories careers job postings culture us benefits privacy policy privacy shield policy terms of use partnering corporate offices us  uk austria belgium canada denmark finland france germany iceland ireland italy luxembourg the netherlands norway portugal spain sweden switzerland uk glossary website privacy policy privacy shield policy terms of use contact us glossary  hudson yards th floor  new york ny   t icpt   intercept pharmaceuticals inc you are now leaving interceptpharmacom you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents intercept provides this link as a service to its website visitors intercept is not responsible for the content or the privacy policy of any third party websites close this window to return to intercept pharma’s site or click ‘continue’ to proceed  you are now being redirected to intercepts job application site hosted by a third party intercept pharmaceuticals  interceptpharmacom careers partnering toggle navigation about about intercept leadership board of directors contact us rd fxr therapeutic focus pbc nash psc alcoholic hepatitis pipeline expanded access discovery compounds scientific presentations patient resources pbc disease information pbc patient stories investors  media press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage investor faqs contact us about  about intercept leadership board of directors contact us rd  fxr therapeutic areas primary biliary cirrhosis nash portal hypertensioncirrhosis bile acid diarrhea pipeline discovery compounds publications and conference materials patient resources  primary biliary cirrhosis nash investors  press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage ownership profile investor faqs contact us home we are intercept our mission is to build a healthier tomorrow for patients with progressive nonviral liver diseases meet ally ally is a mother teacher and motorcycle enthusiast living with liver disease she is also our inspiration read her story  our medicine visit ocalivacom  clinical trials learn about clinical trials that are currently recruiting see more  news find information about our recent press releases events and presentations see more  website privacy policy privacy shield policy terms of use contact us glossary  hudson yards th floor  new york ny   t icpt   intercept pharmaceuticals inc you are now leaving interceptpharmacom you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents intercept provides this link as a service to its website visitors intercept is not responsible for the content or the privacy policy of any third party websites close this window to return to intercept pharma’s site or click ‘continue’ to proceed  you are now being redirected to intercepts job application site hosted by a third party intercept pharmaceuticals  interceptpharmacom careers partnering toggle navigation about about intercept leadership board of directors contact us rd fxr therapeutic focus pbc nash psc alcoholic hepatitis pipeline expanded access discovery compounds scientific presentations patient resources pbc disease information pbc patient stories investors  media press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage investor faqs contact us about  about intercept leadership board of directors contact us rd  fxr therapeutic areas primary biliary cirrhosis nash portal hypertensioncirrhosis bile acid diarrhea pipeline discovery compounds publications and conference materials patient resources  primary biliary cirrhosis nash investors  press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage ownership profile investor faqs contact us home we are intercept our mission is to build a healthier tomorrow for patients with progressive nonviral liver diseases meet ally ally is a mother teacher and motorcycle enthusiast living with liver disease she is also our inspiration read her story  our medicine visit ocalivacom  clinical trials learn about clinical trials that are currently recruiting see more  news find information about our recent press releases events and presentations see more  website privacy policy privacy shield policy terms of use contact us glossary  hudson yards th floor  new york ny   t icpt   intercept pharmaceuticals inc you are now leaving interceptpharmacom you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents intercept provides this link as a service to its website visitors intercept is not responsible for the content or the privacy policy of any third party websites close this window to return to intercept pharma’s site or click ‘continue’ to proceed  you are now being redirected to intercepts job application site hosted by a third party intercept pharmaceuticals  wikipedia intercept pharmaceuticals from wikipedia the free encyclopedia jump to navigation search coordinates °′″n °′″w﻿  ﻿°n °w﻿    intercept pharmaceuticals type public company traded as nasdaq icpt industry biotechnology founded  headquarters new york city new york united states key people mark pruzanski president and ceo jonathan silverstein chairman of the board of directors website wwwinterceptpharmacom intercept pharmaceuticals inc is an american biopharmaceutical company incorporated in  focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases such as primary biliary cirrhosis pbc now called primary biliary cholangitis nonalcoholic fatty liver disease or nonalcoholic steatohepatitis nash cirrhosis portal hypertension primary sclerosing cholangitis and also the intestinal disorder bile acid diarrhea productsedit the companys lead product is obeticholic acid oca also known as ethylchenodeoxycholic acid or int marketed as ocaliva oca is a potent firstinclass farnesoid x receptor fxr agonist as of march  ocaliva is approved in the us and the eu for use in primary biliary cholangitis it is in phase iii studies for nonalcoholic steatohepatitis nash and phase ii studies for primary sclerosing cholangitis other products in the development pipeline include int a dual fxrtgr agonist and int a tgr agonist initial public offering and stock historyedit intercept trades on the nasdaq exchange under the ticker symbol icpt the initial public offering of the stock on october   was at  a followon public offering at  took place on june   on january   the stock skyrocketed from  to  or about  after a planned interim analysis by the independent data safety monitoring board showed that obeticholic acid met the main goal improvement of liver histology at the midstage in the flint trial in nash sponsored by niddk the stock continued to climb to  over the next few days before falling back to around  on march   giving a market capitalization of around  billion in march  the company released the results of the poise study of obeticholic acid in pbc which showed the drug met the trials primary endpoint of a reduction in serum alkaline phosphatase a biomarker for the disease these results were presented at an international liver meeting in april  as of  december  the company had  employees referencesedit  intercept pharmaceuticals strong biopharmaceutical ipo seeking alpha october   retrieved    the farnesoid x receptor fxr ligand obeticholic acid in nash treatment trialflint   intercept pharma press release intercept announces nash primary endpoint met flint trial stopped early for efficacy based on highly statistically significant improvement in liver histology retrieved january     intercept pharma press release intercept announces positive pivotal phase  poise trial results retrieved march     intercepts liver disease drug proves highly effective in study reuters april   retrieved april     intercept pharmaceuticals form k annual report  retrieved october    external linksedit intercept pharmaceuticals website  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleinterceptpharmaceuticalsoldid categories companies listed on nasdaqbiotechnology companies of the united statespharmaceutical companies of the united stateshealth care companies based in new yorkhidden categories coordinates not on wikidatapages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view intercept pharmaceuticals  wikipedia intercept pharmaceuticals from wikipedia the free encyclopedia jump to navigation search coordinates °′″n °′″w﻿  ﻿°n °w﻿    intercept pharmaceuticals type public company traded as nasdaq icpt industry biotechnology founded  headquarters new york city new york united states key people mark pruzanski president and ceo jonathan silverstein chairman of the board of directors website wwwinterceptpharmacom intercept pharmaceuticals inc is an american biopharmaceutical company incorporated in  focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases such as primary biliary cirrhosis pbc now called primary biliary cholangitis nonalcoholic fatty liver disease or nonalcoholic steatohepatitis nash cirrhosis portal hypertension primary sclerosing cholangitis and also the intestinal disorder bile acid diarrhea productsedit the companys lead product is obeticholic acid oca also known as ethylchenodeoxycholic acid or int marketed as ocaliva oca is a potent firstinclass farnesoid x receptor fxr agonist as of march  ocaliva is approved in the us and the eu for use in primary biliary cholangitis it is in phase iii studies for nonalcoholic steatohepatitis nash and phase ii studies for primary sclerosing cholangitis other products in the development pipeline include int a dual fxrtgr agonist and int a tgr agonist initial public offering and stock historyedit intercept trades on the nasdaq exchange under the ticker symbol icpt the initial public offering of the stock on october   was at  a followon public offering at  took place on june   on january   the stock skyrocketed from  to  or about  after a planned interim analysis by the independent data safety monitoring board showed that obeticholic acid met the main goal improvement of liver histology at the midstage in the flint trial in nash sponsored by niddk the stock continued to climb to  over the next few days before falling back to around  on march   giving a market capitalization of around  billion in march  the company released the results of the poise study of obeticholic acid in pbc which showed the drug met the trials primary endpoint of a reduction in serum alkaline phosphatase a biomarker for the disease these results were presented at an international liver meeting in april  as of  december  the company had  employees referencesedit  intercept pharmaceuticals strong biopharmaceutical ipo seeking alpha october   retrieved    the farnesoid x receptor fxr ligand obeticholic acid in nash treatment trialflint   intercept pharma press release intercept announces nash primary endpoint met flint trial stopped early for efficacy based on highly statistically significant improvement in liver histology retrieved january     intercept pharma press release intercept announces positive pivotal phase  poise trial results retrieved march     intercepts liver disease drug proves highly effective in study reuters april   retrieved april     intercept pharmaceuticals form k annual report  retrieved october    external linksedit intercept pharmaceuticals website  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleinterceptpharmaceuticalsoldid categories companies listed on nasdaqbiotechnology companies of the united statespharmaceutical companies of the united stateshealth care companies based in new yorkhidden categories coordinates not on wikidatapages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view intercept pharmaceuticals  wikipedia intercept pharmaceuticals from wikipedia the free encyclopedia jump to navigation search coordinates °′″n °′″w﻿  ﻿°n °w﻿    intercept pharmaceuticals type public company traded as nasdaq icpt industry biotechnology founded  headquarters new york city new york united states key people mark pruzanski president and ceo jonathan silverstein chairman of the board of directors website wwwinterceptpharmacom intercept pharmaceuticals inc is an american biopharmaceutical company incorporated in  focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases such as primary biliary cirrhosis pbc now called primary biliary cholangitis nonalcoholic fatty liver disease or nonalcoholic steatohepatitis nash cirrhosis portal hypertension primary sclerosing cholangitis and also the intestinal disorder bile acid diarrhea productsedit the companys lead product is obeticholic acid oca also known as ethylchenodeoxycholic acid or int marketed as ocaliva oca is a potent firstinclass farnesoid x receptor fxr agonist as of march  ocaliva is approved in the us and the eu for use in primary biliary cholangitis it is in phase iii studies for nonalcoholic steatohepatitis nash and phase ii studies for primary sclerosing cholangitis other products in the development pipeline include int a dual fxrtgr agonist and int a tgr agonist initial public offering and stock historyedit intercept trades on the nasdaq exchange under the ticker symbol icpt the initial public offering of the stock on october   was at  a followon public offering at  took place on june   on january   the stock skyrocketed from  to  or about  after a planned interim analysis by the independent data safety monitoring board showed that obeticholic acid met the main goal improvement of liver histology at the midstage in the flint trial in nash sponsored by niddk the stock continued to climb to  over the next few days before falling back to around  on march   giving a market capitalization of around  billion in march  the company released the results of the poise study of obeticholic acid in pbc which showed the drug met the trials primary endpoint of a reduction in serum alkaline phosphatase a biomarker for the disease these results were presented at an international liver meeting in april  as of  december  the company had  employees referencesedit  intercept pharmaceuticals strong biopharmaceutical ipo seeking alpha october   retrieved    the farnesoid x receptor fxr ligand obeticholic acid in nash treatment trialflint   intercept pharma press release intercept announces nash primary endpoint met flint trial stopped early for efficacy based on highly statistically significant improvement in liver histology retrieved january     intercept pharma press release intercept announces positive pivotal phase  poise trial results retrieved march     intercepts liver disease drug proves highly effective in study reuters april   retrieved april     intercept pharmaceuticals form k annual report  retrieved october    external linksedit intercept pharmaceuticals website  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleinterceptpharmaceuticalsoldid categories companies listed on nasdaqbiotechnology companies of the united statespharmaceutical companies of the united stateshealth care companies based in new yorkhidden categories coordinates not on wikidatapages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view pipeline  intercept pharmaceuticals inc careers partnering toggle navigation about about intercept leadership board of directors contact us rd fxr therapeutic focus pbc nash psc alcoholic hepatitis pipeline expanded access discovery compounds scientific presentations patient resources pbc disease information pbc patient stories investors  media press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage investor faqs contact us about  about intercept leadership board of directors contact us rd  fxr therapeutic areas primary biliary cirrhosis nash portal hypertensioncirrhosis bile acid diarrhea pipeline discovery compounds publications and conference materials patient resources  primary biliary cirrhosis nash investors  press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage ownership profile investor faqs contact us  home  research  development  pipeline learn about clinical trials that are currently recruiting — phase  nash study— phase  pbc study— phase  biliary atresia study we see you at intercept our work is motivated by our desire to help patients and families who struggle with chronic liver diseases and need better treatment options pipeline pipelinenovel compounds being developed for liver diseases intercept’s lead product ocaliva® obeticholic acid was granted accelerated approval by us food and drug administration fda in may of  for the treatment of primary biliary cholangitis previously known as primary biliary cirrhosis pbc in combination with ursodeoxycholic acid udca in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca ocaliva is the first pbc therapy that targets the farnesoid x receptor fxr a key regulator of bile acid inflammatory fibrotic and metabolic pathways for more information please visit ocalivacom obeticholic acid oca is also being evaluated for potential indications across a variety of additional chronic liver diseases including nonalcoholic steatohepatitis nash primary sclerosing cholangitis psc and biliary atresia the pipeline chart below shows the target indications and current stages of development of all of our product candidates formerly known as primary biliary cirrhosis investigators interested in consideration for possible clinical trial participation should complete a questionnaire at click here you are now being directed to intercept’s clinician survey site hosted by fluidsurveys about intercept leadership board of directors contact us rd fxr therapeutic focus pbc nash psc investigator initiated research pipeline expanded access discovery compounds scientific presentations patient resources pbc disease information pbc patient stories careers job postings culture us benefits privacy policy privacy shield policy terms of use partnering corporate offices us  uk austria belgium canada denmark finland france germany iceland ireland italy luxembourg the netherlands norway portugal spain sweden switzerland uk glossary website privacy policy privacy shield policy terms of use contact us glossary  hudson yards th floor  new york ny   t icpt   intercept pharmaceuticals inc you are now leaving interceptpharmacom you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents intercept provides this link as a service to its website visitors intercept is not responsible for the content or the privacy policy of any third party websites close this window to return to intercept pharma’s site or click ‘continue’ to proceed  you are now being redirected to intercepts job application site hosted by a third party investors  media  intercept pharmaceuticals inc careers partnering toggle navigation about  about intercept leadership board of directors contact us rd  fxr therapeutic areas pbc nash psc alcoholic hepatitis pipeline discovery compounds scientific presentations patient resources  pbc disease pbc patient stories investors  media  press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage investor faqs contact us  home investors  media nasdaq icpt      pm et on jul   delayed at least  minutes intra  mo  mo  yr recent press releases jun   intercepts ocaliva® obeticholic acid receives  galien chemical synthesis drug award in italy jun   intercept announces new data analysis from flint trial of oca in nash patients with type  diabetes view all press releases  recent events  presentations jun   at  am pt goldman sachs th annual healthcare conference jun   at  pm et jefferies healthcare conference may   at  pm et ubs global healthcare conference may   at  pm pt bank of america merrill lynch  healthcare conference may   at  am et first quarter  financial results and conference call apr   at  am et th annual needham healthcare conference mar   at  pm th annual healthcare conference mar   at  pm et th annual cowen health care conference feb   at  am et  rbc capital markets global healthcare conference feb   at  am et yearend  financial results and conference call feb   at  am intercept pharmaceuticals inc conference call jan   at  pm pt jp morgan healthcare conference dec   at  pm et bmo prescriptions for success healthcare conference nov   at  am et third quarter  financial results and conference call oct   intercept welcomes you to booth  at the acg annual meeting view all events  presentations  corporate governance  financial information  stock information  investor faqs  contact us  investors  media press releases events  presentations corporate governance financial information stock information contact us shareholder tools briefcase email alerts download library snapshot rss print share facebook google linkedin twitter email rss website privacy policy privacy shield policy terms of use contact us glossary  hudson yards th floor  new york ny   t icpt   intercept pharmaceuticals inc intercept pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals intercept pharmaceuticals inc  product pipeline review   published aug  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample intercept pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘intercept pharmaceuticals inc  product pipeline review  ’ provides an overview of the intercept pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of intercept pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of intercept pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of intercept pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the intercept pharmaceuticals inc’s pipeline products reasons to buy  evaluate intercept pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of intercept pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the intercept pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of intercept pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of intercept pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of intercept pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  intercept pharmaceuticals inc snapshot  intercept pharmaceuticals inc overview  key information  key facts  intercept pharmaceuticals inc  research and development overview  key therapeutic areas  intercept pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  intercept pharmaceuticals inc  pipeline products glance  intercept pharmaceuticals inc  late stage pipeline products  preregistration productscombination treatment modalities  intercept pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  intercept pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  intercept pharmaceuticals inc  drug profiles  obeticholic acid  product description  mechanism of action  rd progress  int  product description  mechanism of action  rd progress  int  product description  mechanism of action  rd progress  intercept pharmaceuticals inc  pipeline analysis  intercept pharmaceuticals inc  pipeline products by target  intercept pharmaceuticals inc  pipeline products by route of administration  intercept pharmaceuticals inc  pipeline products by molecule type  intercept pharmaceuticals inc  pipeline products by mechanism of action  intercept pharmaceuticals inc  recent pipeline updates  intercept pharmaceuticals inc  dormant projects  intercept pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables intercept pharmaceuticals inc key information  intercept pharmaceuticals inc key facts  intercept pharmaceuticals inc  pipeline by indication   intercept pharmaceuticals inc  pipeline by stage of development   intercept pharmaceuticals inc  monotherapy products in pipeline   intercept pharmaceuticals inc  preregistration   intercept pharmaceuticals inc  phase ii   intercept pharmaceuticals inc  phase i   intercept pharmaceuticals inc  preclinical   intercept pharmaceuticals inc  pipeline by target   intercept pharmaceuticals inc  pipeline by route of administration   intercept pharmaceuticals inc  pipeline by molecule type   intercept pharmaceuticals inc  pipeline products by mechanism of action   intercept pharmaceuticals inc  recent pipeline updates   intercept pharmaceuticals inc  dormant developmental projects  intercept pharmaceuticals inc other locations  list of figures intercept pharmaceuticals inc  pipeline by top  indication   intercept pharmaceuticals inc  pipeline by stage of development   intercept pharmaceuticals inc  monotherapy products in pipeline   intercept pharmaceuticals inc  pipeline by top  target   intercept pharmaceuticals inc  pipeline by top  route of administration   intercept pharmaceuticals inc  pipeline by top  molecule type   intercept pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global oncology market to   robust growth driven by rising prevalence and increased uptake of immune checkpoint inhibitors jun  gbi research  pages    code  mrs   global oncology market to   robust growth driven by rising prevalence and increased uptake of immune checkpoint inhibitors summary in  there were  million people living with any type of cancer within five years of diagnosis these are generally incurable once they progress to the stage where they are unresectable chemotherapy compounds are a mainstay treatment for cancers of all types at various disease stages in a typical course of therapy for cancer multiple chemothera read more interleukin  receptor subunit alpha cdw or cd or ilr  pipeline review h  jul  global markets direct  pages    code  mrs   interleukin  receptor subunit alpha cdw or cd or ilr  pipeline review h  summary interleukin  receptor subunit alpha cdw or cd or ilr  interleukin receptor is a protein found on the surface of cells it is a receptor for interleukin it acts as a receptor for thymic stromal lymphopoietin tslp it plays an important role in tcell acute lymphoblastic leukemia multiple sclerosis rheumatoid arthritis and juvenile idiopathic arthritis interleukin  recep read more  kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa  pipeline review h  jul  global markets direct  pages    code  mrs    kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa  pipeline review h  summary  kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa pipeline target constitutes close to  molecules out of which approximately  molecules are devel read more survival motor neuron protein component of gems  or gemin  or smn or smn  pipeline review h  jul  global markets direct  pages    code  mrs   survival motor neuron protein component of gems  or gemin  or smn or smn  pipeline review h  summary according to the recently published report survival motor neuron protein  pipeline review h  survival motor neuron protein component of gems  or gemin  or smn or smn pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies and remaining by the universitiesinstitutes survival motor neuron protein  read more rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   pipeline review h  jul  global markets direct  pages    code  mrs   rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   pipeline review h  summary rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   rhoassociated protein kinase  rock is a protein serinethreonine kinase it is a key regulator of actin cytoskeleton and read more serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec   pipeline review h  jul  global markets direct  pages    code  mrs   serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec   pipeline review h  summary serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec  pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies the latest report serinethreonine protein kinase a raf  pipeline review h  outlays comprehensive information on the serin read more map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec   pipeline review h  jul  global markets direct  pages    code  mrs   map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec   pipeline review h  summary according to the recently published report map kinase interacting serinethreonine protein kinase   pipeline review h  map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec  pipeline target constitutes close to  molecules out of which approximately  molecu read more interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   pipeline review h  jul  global markets direct  pages    code  mrs   interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   pipeline review h  summary interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   interleukin receptorassociated kinase  irak is a protein kinase involved in signaling innate immune responses from tolllike receptors mutations in irak result in irak deficiency and recurrent invasive pneumococcal disease it phosphoryla read more mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec   pipeline review h  jul  global markets direct  pages    code  mrs   mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec   pipeline review h  summary mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec  pipeline target constitutes close to  molecules out of which approximately  molecules are developed by read more protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase h or tgm or ec   pipeline review h  jul  global markets direct  pages    code  mrs   protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase h or tgm or ec   pipeline review h  summary according to the recently published report protein glutamine gamma glutamyltransferase   pipeline review h  protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports intercept pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports intercept pharmaceuticals inc  product pipeline review intercept pharmaceuticals inc  product pipeline review   wgr  june  global  pages global markets direct description table of content sample report enquiry before buy related reports intercept pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘intercept pharmaceuticals inc  product pipeline review  ’ provides an overview of the intercept pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of intercept pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of intercept pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of intercept pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the intercept pharmaceuticals inc’s pipeline productsreasons to buy evaluate intercept pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of intercept pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the intercept pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of intercept pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of intercept pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of intercept pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures intercept pharmaceuticals inc snapshot intercept pharmaceuticals inc overview key information key facts intercept pharmaceuticals inc  research and development overview key therapeutic areas intercept pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy intercept pharmaceuticals inc  pipeline products glance intercept pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities intercept pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities intercept pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities intercept pharmaceuticals inc  drug profiles obeticholic acid product description mechanism of action rd progress int product description mechanism of action rd progress int product description mechanism of action rd progress intercept pharmaceuticals inc  pipeline analysis intercept pharmaceuticals inc  pipeline products by target intercept pharmaceuticals inc  pipeline products by route of administration intercept pharmaceuticals inc  pipeline products by molecule type intercept pharmaceuticals inc  pipeline products by mechanism of action intercept pharmaceuticals inc  recent pipeline updates intercept pharmaceuticals inc  dormant projects intercept pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesintercept pharmaceuticals inc key information intercept pharmaceuticals inc key facts intercept pharmaceuticals inc  pipeline by indication  intercept pharmaceuticals inc  pipeline by stage of development  intercept pharmaceuticals inc  monotherapy products in pipeline  intercept pharmaceuticals inc  phase iii  intercept pharmaceuticals inc  phase ii  intercept pharmaceuticals inc  phase i  intercept pharmaceuticals inc  preclinical  intercept pharmaceuticals inc  pipeline by target  intercept pharmaceuticals inc  pipeline by route of administration  intercept pharmaceuticals inc  pipeline by molecule type  intercept pharmaceuticals inc  pipeline products by mechanism of action  intercept pharmaceuticals inc  recent pipeline updates  intercept pharmaceuticals inc  dormant developmental projects intercept pharmaceuticals inc other locations list of figuresintercept pharmaceuticals inc  pipeline by top  indication  intercept pharmaceuticals inc  pipeline by stage of development  intercept pharmaceuticals inc  monotherapy products in pipeline  intercept pharmaceuticals inc  pipeline by top  target  intercept pharmaceuticals inc  pipeline by top  route of administration  intercept pharmaceuticals inc  pipeline by top  molecule type  intercept pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send icptnasdaq gs stock quote  intercept pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist intercept pharmaceuticals inc icptus nasdaq gs usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  intercept spikes on liver drug study redesign  investopedia  are ma rumors driving intercept pharmas stock  investopedia  intercept liver drug gets conditional eu ok icpt  investopedia there are currently no news stories for this ticker please check back later  am dgapadhoc bb biotech ag tailwind for biotech investors  global cholangiocarcinoma bile duct cancer treatment market revenues worth us  mn by   pmr  cambridge biomarketing honored with multiple industry recognitions  intercept’s ocaliva® obeticholic acid receives  galien chemical synthesis drug award in italy  ovid therapeutics appoints barbara g duncan to its board of directors  syros appoints srinivas akkaraju to its board of directors  intercept announces new data analysis from flint trial of oca in nash patients with type  diabetes  health canada grants approval for ocaliva™ obeticholic acid for the treatment of patients with primary biliary cholangitis  liver fibrosis therapeutic development and pipeline review h  research report now available at rnrmarketresearch  intercept receives innovation award from the national organization for rare disorders for the development of ocaliva® obetich there are currently no press releases for this ticker please check back later profile intercept pharmaceuticals inc manufactures and markets biopharmaceutical products the company focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry intercept pharmaceuticals serves customers throughout the united states address  west th streetsuite new york ny united states phone  website wwwinterceptpharmacom executives board members mark pruzanski presidentceocofounder sandip kapadia cfotreasurer jerome b durso jerry chief operating officer luciano adorini chief scientific officer rachel l mcminn chief business  strategy ofcr show more intercept pharmaceuticals inc icpto company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile intercept pharmaceuticals inc icpto related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse icpto on nasdaq usd pm edt change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description intercept pharmaceuticals inc incorporated on september   is a biopharmaceutical company the company is focused on the development and commercialization of therapeutics to treat nonviral progressive liver diseases the companys product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions the companys product candidate obeticholic acid oca is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid x receptor fxr in addition to oca it is developing other bile acid analog compounds targeting fxr and a second dedicated bile acid receptor called tgr which is a target of interest for the treatment of type  diabetes and other gastrointestinal indications the company is also developing other products int for the treatment of fibrosis and int for the treatment of type  diabetesoca is being developed to treat a range of other nonviral progressive liver diseases such as nonalcoholic steatohepatitis nash primary sclerosing cholangitis psc and biliary atresia oca has been tested in five placebocontrolled clinical trials including a phase iii clinical trial in patients with primary biliary cirrhosis pbc and two phase ii clinical trials in patients with nash or a precursor disease to nash known as nonalcoholic fatty liver disease nafld oca has received orphan drug designation in the united states and the european union for the treatment of pbc and psc and breakthrough therapy designation from the united states food and drug administration fda for the treatment of nash patients with liver fibrosis in addition to pbc and nash it continues to invest in research of oca for additional patient populations with other liver diseasesint is an orally administered dual fxr and tgr agonist that is derived from the primary human bile acid chenodeoxycholic acid cdca this product candidate has been shown to be approximately three times more potent than oca as an fxr agonist in animal models of chronic liver intestinal and kidney diseases int has consistently demonstrated greater antifibrotic and antiinflammatory effects than oca int is an orally administered tgr agonist that is derived from the primary human bile acid cholic acid it has completed the preclinical studies necessary for the filing of an investigational new drug ind in animal models of diabetes treatment with int induced glucagon like peptide glp secretion with resulting insulin sensitivity and normalization of glycemic control increased basal energy expenditure and prevention of weight gain and a reduction in blood lipid levels together with liver steatosis and fibrosisthe company competes with novartis international ag gilead sciences inc allergan plc enanta pharmaceuticals inc enyo pharma sas metacrine inc genfit sa cymabay therapeutics inc bristolmyers squibb co ff pharmaceuticals bv glaxosmithkline novo nordisk as conatus pharmaceuticals inc cempra pharmaceuticals islet sciences inc galectin therapeutics inc zydus pharmaceuticals inc ngm biopharmaceuticals inc galmed medical research ltd medicinova inc ionis pharmaceuticals inc fibrogen inc viking therapeutics inc astrazeneca plc durect corporation immuron ltd boehringer ingelheim gmbh mina therapeutics nusirt biopharma inc protalix biotherapeutics medivation inc acorda therapeutics inc dr falk pharma gmbh and shire plc » full overview of icpto company address intercept pharmaceuticals inc  hudson yards fl new york   ny    p f  company web links home page officers  directors name compensation paolo fundaro  mark pruzanski  sandip kapadia  lisa bright  jerome durso  » more officers  directors intercept pharmaceuticals inc news briefintercept announces new data analysis from flint trial of oca jun   briefhealth canada grants approval for ocaliva may   briefintercept pharmaceuticals files for potential mixed shelf offering may   briefintercept pharmaceuticals reports q sales  mln feb   briefintercept pharmaceuticals to update on trial of liver fibrosis treatment feb   » more icpto news related topics stocksstock screenerhealthcarebiotechnology  medical research intercept pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report intercept pharmaceuticals inc  product pipeline review   published by global markets direct product code  published august   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license intercept pharmaceuticals inc  product pipeline review   published august   content info  pages description summary global markets directs intercept pharmaceuticals inc  product pipeline review   provides an overview of the intercept pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of intercept pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of intercept pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of intercept pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the intercept pharmaceuticals incs pipeline products reasons to buy evaluate intercept pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of intercept pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the intercept pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of intercept pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of intercept pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of intercept pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdb table of contents table of contents list of tables list of figures intercept pharmaceuticals inc snapshot intercept pharmaceuticals inc overview key information key facts intercept pharmaceuticals inc  research and development overview key therapeutic areas intercept pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy intercept pharmaceuticals inc  pipeline products glance intercept pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities intercept pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities intercept pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities intercept pharmaceuticals inc  drug profiles obeticholic acid product description mechanism of action rd progress int product description mechanism of action rd progress int product description mechanism of action rd progress intercept pharmaceuticals inc  pipeline analysis intercept pharmaceuticals inc  pipeline products by target intercept pharmaceuticals inc  pipeline products by route of administration intercept pharmaceuticals inc  pipeline products by molecule type intercept pharmaceuticals inc  pipeline products by mechanism of action intercept pharmaceuticals inc  recent pipeline updates intercept pharmaceuticals inc  dormant projects intercept pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables intercept pharmaceuticals inc key information intercept pharmaceuticals inc key facts intercept pharmaceuticals inc  pipeline by indication  intercept pharmaceuticals inc  pipeline by stage of development  intercept pharmaceuticals inc  monotherapy products in pipeline  intercept pharmaceuticals inc  preregistration  intercept pharmaceuticals inc  phase ii  intercept pharmaceuticals inc  phase i  intercept pharmaceuticals inc  preclinical  intercept pharmaceuticals inc  pipeline by target  intercept pharmaceuticals inc  pipeline by route of administration  intercept pharmaceuticals inc  pipeline by molecule type  intercept pharmaceuticals inc  pipeline products by mechanism of action  intercept pharmaceuticals inc  recent pipeline updates  intercept pharmaceuticals inc  dormant developmental projects intercept pharmaceuticals inc other locations list of figures intercept pharmaceuticals inc  pipeline by top  indication  intercept pharmaceuticals inc  pipeline by stage of development  intercept pharmaceuticals inc  monotherapy products in pipeline  intercept pharmaceuticals inc  pipeline by top  target  intercept pharmaceuticals inc  pipeline by top  route of administration  intercept pharmaceuticals inc  pipeline by top  molecule type  intercept pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved intercept pharmaceuticals inc  icpt  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  b dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research reports for icpt     all zacks’ analyst reports premium research for icpt zacks rank hold  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores f value  f growth  a momentum  f vgm earnings esp  research reports for icpt analyst  snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank intercept pharmaceuticals inc icpt enzo biochem inc enz exelixis inc exel vertex pharmaceuticals incorporated vrtx amag pharmaceuticals inc amag abeona therapeutics inc abeo acceleron pharma inc xlrn see all medical  biomedical and genetics peers zacks news for icpt what to expect from keryx kerx this earnings season am est zacks is a beat in store for alexion alxn this earnings season am est zacks icpt what are zacks experts saying now zacks private portfolio services intercept icpt releases data from phase ii flint trial am est zacks intercept icpt down  since earnings report can it rebound am est zacks intercept pharmaceuticals icpt looks good stock adds  in session am est zacks company summary intercept pharmaceuticals inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease the companys lead product candidate obeticholic acid or oca is a bile acid analog and firstinclass agonist of the farnesoid x receptor fxr oca is initially being developed for the second line treatment of primary biliary cirrhosis pbc intercept pharmaceuticals inc is headquartered in new york microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft goboldly  latest news and stories from the american biopharmaceutical industry skip to main content explore the innovative research and technological breakthroughs of americas biopharmaceutical industry and get to know the people behind the fight to prevent treat and cure disease our fight our mission our companies follow us  pharmaceutical research and manufacturers of america  f street nw suite  washington dc   p   f phrmaorg innovationorg privacy policy terms of service aboutus finding lifesaving medicines is a lifes work – the work of  researchers who never say never as well as the millions of patients who fight side by side with researchers in the battle for life against whatever odds they face together now is the time to put the accelerator to the floor the best is yet to come – like advancements in personalized medicine and immunotherapy – and its coming faster than we can imagine welcome to the future of medicine where disease is no match for tenacity no match for ingenuity where together we go boldly do not go gentle todays breakthroughs are becoming tomorrows medicines watch the video do not go gentle do not go gentle share tweet link email print this is the most exciting time in the history of medicine millions of people around the world are benefiting from breakthrough treatments that save extend and improve life research technology and genomics are coming together to create a platform that allows researchers to decipher the cause of disease as never before each advance opens new doors new cures new treatments and yet it’s not enough todays breakthroughs become tomorrows medicines tweet cures don’t appear on a schedule in search of the unknowable in search of curing the incurable there is no one map no singular template no predictable milestones finding lifesaving medicines is a life’s work – the work of thousands of researchers who never say never its also the work of millions of patients who fight side by side with researchers in the battle for life against whatever odds they face together now is the time to put the accelerator to the floor the best is yet to come – like groundbreaking advances in immunotherapy and personalized medicine – where the once impossible is now reality welcome to the future of medicine where disease is no match for tenacity no match for ingenuity where together we go boldly dylan thomas penned do not go gentle into that good night in  but the sentiment is as timely today as it ever was millions of americans are battling serious illnesses but they’re not alone in the fight they have the support of thousands of biopharmaceutical researchers whose lives are dedicated to helping patients go boldly into longer healthier and more productive lives   related news the power of medicines saving lives and creating hope for the future view the graphic driving personalized medicine forward the biopharmaceutical industry is leading the charge in finding new medicines for patients view the gallery translating science into new medicines the commitment it takes for researchers and scientists to achieve breakthroughs in medicine watch the video share tweet link email print goboldly  latest stories from the american biopharmaceutical industry  cells one skip to main content explore the innovative research and technological breakthroughs of americas biopharmaceutical industry and get to know the people behind the fight to prevent treat and cure disease our fight our mission our companies follow us  pharmaceutical research and manufacturers of america  f street nw suite  washington dc   p   f phrmaorg innovationorg privacy policy terms of service aboutus finding lifesaving medicines is a lifes work – the work of  researchers who never say never as well as the millions of patients who fight side by side with researchers in the battle for life against whatever odds they face together now is the time to put the accelerator to the floor the best is yet to come – like advancements in personalized medicine and immunotherapy – and its coming faster than we can imagine welcome to the future of medicine where disease is no match for tenacity no match for ingenuity where together we go boldly do not go gentle todays breakthroughs are becoming tomorrows medicines watch the video a new way to fight cancer a new way to fight cancer share tweet link email print it used to be science fiction harnessing your body’s own immune system to fight cancer but what was once the fruit of a wild imagination is today a reality rather than killing cancer cells directly with traditional approaches like radiation or chemotherapy immunotherapy harnesses the immune system’s power to eliminate the cancer or slow its growth and ability to spread research shows immunotherapy is improving outcomes and survival rates for some patients including kidney and lung cancer in fact research from the american association for cancer research shows that for advancedmelanoma patients survival rates are improving thanks in part to these new treatment options it used to be science fiction harnessing your body’s own immune system to fight cancer tweet biopharmaceutical researchers are urgently working to gain new insights into the complex interactions between patients’ immune systems and the cancer cells growing in their bodies with the goal of markedly improving outcomes in more tumor types with  medicines and vaccines in development for cancer  percent of which have the potential to be firstinclass treatments millions of americans living with cancer have hope for a brighter future welcome to the new era of medicine for all of us   related news translating science into new medicines the commitment it takes for researchers and scientists to achieve breakthroughs in medicine watch the video driving personalized medicine forward the biopharmaceutical industry is leading the charge in finding new medicines for patients view the gallery the power of medicines saving lives and creating hope for the future view the graphic share tweet link email print goboldly  latest stories from the american biopharmaceutical industry  personalized medicine skip to main content explore the innovative research and technological breakthroughs of americas biopharmaceutical industry and get to know the people behind the fight to prevent treat and cure disease our fight our mission our companies follow us  pharmaceutical research and manufacturers of america  f street nw suite  washington dc   p   f phrmaorg innovationorg privacy policy terms of service aboutus finding lifesaving medicines is a lifes work – the work of  researchers who never say never as well as the millions of patients who fight side by side with researchers in the battle for life against whatever odds they face together now is the time to put the accelerator to the floor the best is yet to come – like advancements in personalized medicine and immunotherapy – and its coming faster than we can imagine welcome to the future of medicine where disease is no match for tenacity no match for ingenuity where together we go boldly do not go gentle todays breakthroughs are becoming tomorrows medicines watch the video the promise of personalized medicine the promise of personalized medicine share tweet link email print phrma’s member companies are on the leading edge of personalized medicine development– an area that is transforming health care improving patient outcomes and creating health system efficiencies in a new video dr bernie zeiher president of development of astellas discusses his excitement around the promise of personalized medicine which uses diagnostic tools to help assess the medical treatments and procedures that may be best for each patient “i am very optimistic about the future because the promise of personalized medicine has begun to be seen” dr zeiher says in the video “now with more personalizedtype therapies you can test the tumor or test the blood to determine that in fact the person has a particular mutation and then that will guide which therapy you would choose and it also increases the likelihood that the patient will respond” dr zeiher’s enthusiasm reflects the commitment of america’s biopharmaceutical companies to the development of these targeted treatments although there were only  fdaapproved personalized medicines in  today there are more than  additionally personalized medicines accounted for more than  percent of fda approvals last year marking a record year for these innovative therapies cancer is an area where personalized medicines are having a particularly big impact driving tremendous advances for patients with highly aggressive cancers like nonsmall cell lung cancer nsclc in fact research has shown nearly twothirds of nslcs have a genetic mutation that can be more effectively targeted with a personalized medicine thanks to the hard work of biopharmaceutical researchers like dr zeiher  percent of medications currently in the pipeline have the potential to be personalized while the science has never been more complex the future of research is bright with personalized medicine becoming a reality to learn more about the promise of personalized medicines visit phrma’s innovation hub related news driving personalized medicine forward the biopharmaceutical industry is leading the charge in finding new medicines for patients view the gallery targeting the immune system not the tumor recent scientific discoveries and clinical advances are ushering in a new era for cancer research  watch the video share tweet link email print interceptor for dogs  cats  heartworm medicine  petmeds  offcoupon code save   off wcode save free shipping   satisfaction guaranteed  my account my account my orders my settings reorder sign in create account contact us reorder view cart products productseducation my account my account my orders my settings reorder contact us sign in create account dog dog categories flea  tick heartworm pain joints medications skin  coat vitamins dental ear supplies food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers cat cat categories flea  tick heartworm pain joints medications skin  coat vitamins dental ear supplies food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers flea  tick flea  tick categories flea  tick prevention flea pills  oral medications heartworm  flea prevention home  yard treatments immediate relief sprays  shampoos tick  flea collars heartworm pain joints joints categories joint pain joint supplements lift harnesses  slings orthopedic beds steps  ramps medications medications categories allergy relief antibiotics antifungal anxiety asthma compound medications cough relief digestive support  enzymes diuretics heart  blood pressure hormonal endocrine incontinence insulin  diabetes nausea  motion sickness pain seizure  epilepsy thyroid urinary tract  kidneys wormers skin  coat skin  coat categories allergy relief antibacterials fish oils  omega  grooming tools hairball remedies itch relief ringworm treatments shampoos shedding remedies skin care supplements skin medications vitamins vitamins categories antioxidants calcium dietary digestive enzymes fish oils  omega  food additives liver support multivitamins potassium senior support dental dental categories breath fresheners chews  treats rinses  water additives toothpaste  toothbrushes ear ear categories ear cleaners ear infection remedies ear mite treatments supplies supplies categories beds bowls  automatic feeders carriers car seats  seat covers cat furniture crates  kennels first aid furniture covers gates grooming tools leashes  harnesses litter boxes  accessories outdoor cat enclosures pet food storage shampoos stain  odor removers steps  ramps strollers toys training aids treats water fountains wireless dog fences more food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers new education home heartworm heartworm prevention errors interceptor rx info  well ask for your vets info during checkout  we verify your prescription and ship your order close  starts    ships in one business day or less  select pets weight dog  lbs  lbs  lbs  lbs  up  select a supply  pack    price wcoupon save free shipping temporarily out of stock  pack    price wcoupon save free shipping save  over  pk temporarily out of stock  pack    price wcoupon save free shipping save  over  pk temporarily out of stock starts    ships in one business day or less temporarily out of stock select pets weight pets weight dog  lbs pets weight dog  lbs pets weight dog  lbs pets weight dog  lbs  up select a supply pack   pack   pack                                 add to cart please select all product options  select a quantity quantity                               add to cart please select all product options product info how to use ingredients customer reviews qa product info what is k advantix ii k advantix ii is a monthly preventative for dogs that offers comprehensive protection against ticks fleas mosquitoes biting flies and chewing lice k advantix ii is a top veterinarianrecommended brand because it repels and kills all life stages of fleas eggs pupae larvae and adult fleas and ticks deer ticks american dog ticks brown dog ticks and lone star ticks k advantix ii kills  percent of fleas within  hours and continues working for one month to prevent infestations fleas and ticks are killed on contact with a treated dog which means that fleas dont have to bite and ticks dont have to attach to die this helps prevent transmission of fleaborne and tickborne diseases such as tapeworms lyme disease tick paralysis ehrlichia and rocky mountain spotted fever killing fleas before they bite may also help prevent skin allergies caused by flea saliva as well k advantix ii repels mosquitoes before they bite which may help prevent transmission of heartworms k advantix ii protects your pet before parasites have a chance to bite not afterfor dogs and puppies only over  lbs and  weeks of age or olderbenefits repels and kills diseasecarrying fleas ticks and mosquitoes before they bite kills all life stages of fleas eggs pupae larvae and adult fleas and ticks deer ticks american dog ticks brown dog ticks and lone star ticks kills  percent of adult fleas within  hoursends flea life cycle by preventing flea offspring eggs pupae and larvae from maturing into adult fleasrepels biting flies and kills chewing liceprovides one month of protection against ticks fleas mosquitoes biting flieswaterproof  continues working even after your dog becomes wethow k advantix ii worksk advantix ii combines imidacloprid and permethrin to repel and kill fleas ticks and mosquitoes both ingredients work on contact attacking parasite nerve cells at different sites together these ingredients overwhelm the nervous system killing the parasite pyriproxyfen is an insect growth regulator k advantix ii topical solution also repels biting flies and kills licecautionsdo not use on cats cats cannot metabolize the ingredients used in this product cats must be separated from dogs during treatment do not allow your cat to come in contact with a treated dog for  hours some small and medium dogs may have an adverse skin reaction brand name k advantix ii bayeractive ingredients imidacloprid  permethrin  pyriproxyfen  other ingredients  what is this product used for k advantix ii is for use on dogs and puppies  lbs or more and  weeks of age or older only it is used for the topical prevention and treatment of ticks fleas mosquitoes biting flies and chewing lice on dogs repels and kills ticks including deer ticks the major carrier of lyme disease american dog ticks brown dog ticks and lone star ticks k advantix ii repels and kills all life stages of fleas repels and kills mosquitoes kills chewing lice and repels biting flies availability k advantix ii is a nonprescription otc product available as  fl oz  ml applicators for dogs  lbs green  fl oz  ml applicators for dogs  lbs teal  fl oz  ml applicators for dogs  lbs red and  fl oz  ml applicators for dogs over  lbs blue how this product should be used for use only on dogs do not use on cats or on other animals have the dog standing for easy application part the hair on the dogs back between the shoulder blades until the skin is visible for dogs up to  lbs apply the entire contents of the applicator tube to  or  spots on the top of the back from the shoulder to the base of the tail for dogs  lbs and over apply the entire contents of the applicator tube to  or  spots on the top of the back from the shoulder to the base of the tail if the household has cats or other animals separate from the treated dog for  hours what are the side effects individual sensitivities while rare may occur after using any pesticide product for pets a small percentage of dogs have had adverse reactions to k advantix ii a sensation of burning tingling itching redness or numbness of the skin may occur after topical application this sensation usually begins  hours after application in addition reactions have occurred in cats that have been exposed to a medicated dog that is why it is important to separate your cat from a medicated dog for  hours bayer the manufacturer of k advantix ii indicates that some of these symptoms will dissipate within  hours however if your pet is experiencing adverse reactions please complete the following steps stop applying the medication wash your dog with a detergent based soap dawn or palmolive dish detergents work best do not scrub the affected area as this may cause more skin irritation please note this process is applicable for both dogs and cats call your veterinarian call bayer emergency support line at  let bayer know your dog is having an adverse reaction to k advantix by calling  this line is staffed  hours a day  days a week what special precautions are there this product is for external use only on dogs and puppies  lbs or more and  weeks or older consult a veterinarian before using on medicated animals and debilitated aged pregnant or nursing animals do not get this product in dogs eyes or mouth do not use this product on animals other than dogs in households with cats separate the treated dog for about  hours due to their unique physiology and inability to metabolize certain compounds this product must not be used on cats if applied to a cat or ingested by a cat which actively grooms a recently treated dog this product may have serious harmful effects if this occurs contact your veterinarian immediately it is important to apply this product no more than once a month and to use the correct strength for the weight of the dog this product is harmful to humans if swallowed call a physician or poison control center for advice have patient sip water do not induce vomiting unless advised to and the patient is conscious this product can cause eye irritation flush eyes with plenty of water call a physician if irritation persists avoid contact with skin eyes or clothing wash thoroughly with soap and water after handling in the event of overdose contact your veterinarian or veterinary emergency room how should i store this product store this product in a cool dry place do not refrigerate store in the original container only do not reuse original container if the container is empty place in trash or offer for recycling if available if the container is partially filled call for disposal instructions never place unused product down any indoor or outdoor drain how to use directionsuse only on dogs over  lbs and over  weeks of age do not use on cats or on other animalsyour dog should be standing for easy applicationthe entire contents of k advantix ii tube should be applied evenly to the top of the back from the shoulder to the base of the tailat each spot part the hair until the skin is visible place the tip of the tube on the skin and gently squeeze to expel a portion of the solution on the skindo not apply an excessive amount of solution at any one spot that could cause some of the solution to run off the side of your dogfor dogs up to  lbs apply the entire contents of the applicator tube to  or  spots on the top of the back from the shoulder to the base of the tailfor dogs  lbs and over apply the entire contents of the applicator tube to  or  spots on the top of the back from the shoulder to the base of the tailuse only one applicator per treatment tip in households with cats separate the treated dog for  hours until the product is thoroughly dry visit k advantix ii adverse reactions if your pet has been experiencing adverse reactions to k advantix ii dosagedogspuppies weeks of age and olderweightdosage lbsdo not use lbsapply contents of  applicator once a month green box lbsapply contents of  applicator once a month teal box lbsapply contents of  applicator once a month red boxover  lbsapply contents of  applicator once a month blue boxcatsdo not usehorsesdo not usestorage should be stored in a cool dry place do not refrigerate ingredients k advantix ii for dogs  lbs small dog  green box  mlactive ingredients per applicator tube by weightimidaclopridpermethrinpyriproxyfenother ingredients not specifiedcistrans ratio max   cis and min   transk advantix ii for dogs  lbs medium dog  teal box  mlactive ingredients per applicator tube by weightimidaclopridpermethrinpyriproxyfenother ingredients not specifiedcistrans ratio max   cis and min   transk advantix ii for dogs  lbs large dog  red box  mlactive ingredients per applicator tube by weightimidaclopridpermethrinpyriproxyfenother ingredients not specifiedcistrans ratio max   cis and min   transk advantix ii for dogs over  lbs extra large dog  blue box  mlactive ingredients per applicator tube by weightimidaclopridpermethrinpyriproxyfenother ingredients not specifiedcistrans ratio max   cis and min   trans customer reviews k advantix ii is rated  out of  by  rated  out of  by terry from product didnt work last summer i spent well over  for three different sized dogs on k advantix ii and one week later they were all fully loaded with fleas scratching their fur out and whinning uncontrollably so dissatisfied with this product wont purchase this again date published  rated  out of  by bert from works well on my dogs ive used it for years and no fleas on my dogs date published  rated  out of  by grannymjh from great product was using frontline and my sister told me about this productwe live in the south where fleas and ticks are badit works great well pleased date published  rated  out of  by paulette from happy dog i bought this product a week ago and my dog now is flea freehe can now sleep and go for walksso far so goodlets see if it lasts a month date published  rated  out of  by andrea from pet meds is great i contact pet meds about my dog bella who has seizures it seemed like the fleaand heart worm medication would bring it on spoke with therepet adviser they suggested to split the flea med and wait two weeks and give heartworm i am so happy to say first time she didnt have a seizure thanks for the great advice date published  rated  out of  by samantha from greatest overall protection we live in s florida where we are inundated with all types of tiny creatures year round  our dogs are very susceptible to fleas ticks  especially mosquitoes which here have been known to carry the zika virus this is the only product out there that protects our babies from everything including mosquitoes they have never yet had a mosquito bite great protection date published  rated  out of  by jojo from stops misquitos from biting alsobest of all date published  rated  out of  by david from great tasting come to think of it neither dogs ever had a tick it must be the product that is successfully protecting my furkids enough about me lets talk about you what do you think of me petmeds has really been fiscally supportive by offering top quality products many choices at a lower price thanks date published  k advantix ii reviews  page  y m d h bvseobulk prodbvrr vnbulk cp bvpage cohasreviews tv tr locenus sidprod prod sortsortentryordersubmissiontime directiondescending clientnamepetmeds qa okay so my dog used to have heartworms and i just want to know can i use this with heart guard plus or does it protect against them alone and if so will it work as well as heartguard plus i dont want her to get heartworms againnbsp asked by anniesmom k advantix helps prevent the transmission of heartworms it does not protect against your dog getting heartworms adding heartgard plus is safe and will work better to protect your dog against getting heartworms answered by ben b date published  do you deliver to canada asked by frckls yes answered by amy petmed pro date published  doe k advantix ii have the tick and fleas and mosquitoes in pill form thanks betty asked by none the k advantix medication only comes as an applicator to be applied topically on the dog there is no pill form there are other medications however that are pills and can be taken orally that work against fleas ticks and mosquitos i would talk to your vet about these options and what is best for your dog answered by trey w date published  why is the price almost  dollars more today then yesterday when checked then u offer a coupon asked by debbie it may be that the coupon amount has changed from the usual  to  for a limited time and you caught the website in the process of changing numbers around answered by suzycvt date published  will k advantix protect my dog from fire ants asked by larry the labeling of this product does not indicate protection from fire ants answered by amy petmed pro date published  hi my chihuahua is on the border line on weight she goes between  lbs which kadvantage ii should i get for her asked by lola i am very sorry we can only advise to administer the medication the way the manufacturer intended which is by weight class answered by amy petmed pro date published  can i use shampoo to wash my dogs asked by thom wen is very gentle i use sweet almond mint it conditions as it cleanses they also have  just for pets no one care more for dogs than chaz dean he brings his dogs to shows amp they r beautiful my dog is black after  wks her coat still shines all colors in sun light qvc has chaz on a lot prices best there btw is doesnt make lather but skin amp coat soft amp shiny answered by lola date published  how many applications is there in one boxnbsp asked by debbie its best to get the  pk if you can afford it because fleas are around  months of the year now thanks to global warming the larger pkg the better savings you will get amp god forbid if something happen to your family pet you can donate whats left over to your vet office for people that cant afford it my vet has an angel fund for families that need help answered by lola date published  k advantix ii questions  page  y m d hcst bvseobulk prodbvqa vnbulk cp bvpage cohasquestionsanswers tq locenus sidprod prod sortsortentryorderlastapprovedanswersubmissiontime directiondescending clientnamepetmeds help  customer service about us contact us faq printable order form pet education vet directory request a catalog vetvipps accreditation my account login email preferences reorder easy refill track my order my account page my pet has passed away petmeds® programs affiliate program shelter  rescue program free pet meds join our social network email us call us  help  customer service live chat about us contact us faq printable order form pet education vet directory request a catalog vetvipps accreditation my account login email preferences reorder easy refill track my order my account page my pet has passed away petmeds® programs affiliate program shelter  rescue program free pet meds join our social network copyright   petmed express inc all rights reserved close live chat share website feedback name email phone feedback relief from fleas  ticks for pets  petmeds  offcoupon code save   off wcode save free shipping   satisfaction guaranteed  my account my account my orders my settings reorder sign in create account contact us reorder view cart products productseducation my account my account my orders my settings reorder contact us sign in create account dog dog categories flea  tick heartworm pain joints medications skin  coat vitamins dental ear supplies food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers cat cat categories flea  tick heartworm pain joints medications skin  coat vitamins dental ear supplies food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers flea  tick flea  tick categories flea  tick prevention flea pills  oral medications heartworm  flea prevention home  yard treatments immediate relief sprays  shampoos tick  flea collars heartworm pain joints joints categories joint pain joint supplements lift harnesses  slings orthopedic beds steps  ramps medications medications categories allergy relief antibiotics antifungal anxiety asthma compound medications cough relief digestive support  enzymes diuretics heart  blood pressure hormonal endocrine incontinence insulin  diabetes nausea  motion sickness pain seizure  epilepsy thyroid urinary tract  kidneys wormers skin  coat skin  coat categories allergy relief antibacterials fish oils  omega  grooming tools hairball remedies itch relief ringworm treatments shampoos shedding remedies skin care supplements skin medications vitamins vitamins categories antioxidants calcium dietary digestive enzymes fish oils  omega  food additives liver support multivitamins potassium senior support dental dental categories breath fresheners chews  treats rinses  water additives toothpaste  toothbrushes ear ear categories ear cleaners ear infection remedies ear mite treatments supplies supplies categories beds bowls  automatic feeders carriers car seats  seat covers cat furniture crates  kennels first aid furniture covers gates grooming tools leashes  harnesses litter boxes  accessories outdoor cat enclosures pet food storage shampoos stain  odor removers steps  ramps strollers toys training aids treats water fountains wireless dog fences more food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers new education home flea  tick immediate relief show results by pet type cat   dog   category immediate relief  flea  tick prevention  flea pills  oral medications  heartworm  flea prevention  home  yard treatments  sprays  shampoos  tick  flea collars  brand petmeds   advantage   bio spot   capstar   frontline   natural chemistry   perfect coat   resco   resultix   seresto   ticksee   more price            immediate relief cant decide learn more compare up to  products compare selected  show  items  items  items sort by popularity high to low products a to z rating high to low price low to high filter by sort by show results by pet type cat   dog   category immediate relief  flea  tick prevention  flea pills  oral medications  heartworm  flea prevention  home  yard treatments  sprays  shampoos  tick  flea collars  brand petmeds   advantage   bio spot   capstar   frontline   natural chemistry   perfect coat   resco   resultix   seresto   ticksee   more price            popularity high to low products a to z rating high to low price low to high seresto    compare fleax plus  generic to frontline plus  starts   compare capstar flea treatment tablets    compare frontline spray  starts   compare advantus oral flea treatment soft chews for dogs  starts   compare bio spot flea  tick collar for cats    compare be flea free shampoo    compare advantage treatment spray    compare ticksee tick removal kit   compare natural chemistry natural flea  tick shampoo with oatmeal    compare natural chemistry de flea pet  bedding spray    compare perfect coat flea  tick dog shampoo    compare be flea free spray    compare natural chemistry natural flea  tick spray for dogs    compare resco proseries flea comb    compare natural chemistry natural flea spray for cats    compare resultix    compare help  customer service about us contact us faq printable order form pet education vet directory request a catalog vetvipps accreditation my account login email preferences reorder easy refill track my order my account page my pet has passed away petmeds® programs affiliate program shelter  rescue program free pet meds join our social network email us call us  help  customer service live chat about us contact us faq printable order form pet education vet directory request a catalog vetvipps accreditation my account login email preferences reorder easy refill track my order my account page my pet has passed away petmeds® programs affiliate program shelter  rescue program free pet meds join our social network copyright   petmed express inc all rights reserved close live chat share website feedback name email phone feedback flea  tick control and prevention for pets  petmeds  offcoupon code save   off wcode save free shipping   satisfaction guaranteed  my account my account my orders my settings reorder sign in create account contact us reorder view cart products productseducation my account my account my orders my settings reorder contact us sign in create account dog dog categories flea  tick heartworm pain joints medications skin  coat vitamins dental ear supplies food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers cat cat categories flea  tick heartworm pain joints medications skin  coat vitamins dental ear supplies food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers flea  tick flea  tick categories flea  tick prevention flea pills  oral medications heartworm  flea prevention home  yard treatments immediate relief sprays  shampoos tick  flea collars heartworm pain joints joints categories joint pain joint supplements lift harnesses  slings orthopedic beds steps  ramps medications medications categories allergy relief antibiotics antifungal anxiety asthma compound medications cough relief digestive support  enzymes diuretics heart  blood pressure hormonal endocrine incontinence insulin  diabetes nausea  motion sickness pain seizure  epilepsy thyroid urinary tract  kidneys wormers skin  coat skin  coat categories allergy relief antibacterials fish oils  omega  grooming tools hairball remedies itch relief ringworm treatments shampoos shedding remedies skin care supplements skin medications vitamins vitamins categories antioxidants calcium dietary digestive enzymes fish oils  omega  food additives liver support multivitamins potassium senior support dental dental categories breath fresheners chews  treats rinses  water additives toothpaste  toothbrushes ear ear categories ear cleaners ear infection remedies ear mite treatments supplies supplies categories beds bowls  automatic feeders carriers car seats  seat covers cat furniture crates  kennels first aid furniture covers gates grooming tools leashes  harnesses litter boxes  accessories outdoor cat enclosures pet food storage shampoos stain  odor removers steps  ramps strollers toys training aids treats water fountains wireless dog fences more food allergy relief arthritis eye hormonal endocrine urinary tract  kidneys wormers new education home flea  tick flea  tick prevention show results by pet type cat   dog   category flea  tick prevention  flea pills  oral medications  heartworm  flea prevention  home  yard treatments  immediate relief  sprays  shampoos  tick  flea collars  brand petmeds   activyl   activyl tick plus   advantage ii   advantage multi   bio spot   bravecto   cheristin   comfortis   easyspot   frontline plus   k advantix ii   nexgard   parastar   parastar plus   petarmor   preventic   revolution   scalibor   sentinel   sentinel spectrum   seresto   simparica   trifexis   more price            flea  tick prevention cant decide learn more compare up to  products compare selected  show  items  items  items sort by popularity high to low products a to z rating high to low price low to high filter by sort by show results by pet type cat   dog   category flea  tick prevention  flea pills  oral medications  heartworm  flea prevention  home  yard treatments  immediate relief  sprays  shampoos  tick  flea collars  brand petmeds   activyl   activyl tick plus   advantage ii   advantage multi   bio spot   bravecto   cheristin   comfortis   easyspot   frontline plus   k advantix ii   nexgard   parastar   parastar plus   petarmor   preventic   revolution   scalibor   sentinel   sentinel spectrum   seresto   simparica   trifexis   more price            popularity high to low products a to z rating high to low price low to high nexgard chewables  starts   compare k advantix ii  starts   compare bravecto  starts   compare revolution  starts   compare frontline plus  starts   compare trifexis  starts   compare advantage ii  starts   compare seresto    compare fleax plus  generic to frontline plus  starts   compare sentinel  starts   compare comfortis  starts   compare advantage multi  starts   compare sentinel spectrum  starts   compare simparica  starts   compare cheristin for cats    compare bravecto for cats  starts   compare petarmor  generic to frontline top spot  starts   compare parastar plus for dogs  starts   compare parastar for dogs  starts   compare scalibor protector band for dogs    compare activyl tick plus  starts   compare preventic amitraz tick collar for dogs    compare activyl  starts   compare easyspot for cats  starts   compare bio spot active care flea  tick collar for dogs    compare bio spot flea  tick collar for cats    compare bio spot for cats    compare catego for cats starts   compare help  customer service about us contact us faq printable order form pet education vet directory request a catalog vetvipps accreditation my account login email preferences reorder easy refill track my order my account page my pet has passed away petmeds® programs affiliate program shelter  rescue program free pet meds join our social network email us call us  help  customer service live chat about us contact us faq printable order form pet education vet directory request a catalog vetvipps accreditation my account login email preferences reorder easy refill track my order my account page my pet has passed away petmeds® programs affiliate program shelter  rescue program free pet meds join our social network copyright   petmed express inc all rights reserved close live chat share website feedback name email phone feedback internal error  error weve reported it to the team try again intercept pharmaceuticals icpt  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in intercept pharmaceuticals inc icpt median target price   upside positive ratings  of  analysts latest  jefferies  buy     view all analyst ratings for icpt » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » intercept pharmaceuticals  wikipedia intercept pharmaceuticals from wikipedia the free encyclopedia jump to navigation search coordinates °′″n °′″w﻿  ﻿°n °w﻿    intercept pharmaceuticals type public company traded as nasdaq icpt industry biotechnology founded  headquarters new york city new york united states key people mark pruzanski president and ceo jonathan silverstein chairman of the board of directors website wwwinterceptpharmacom intercept pharmaceuticals inc is an american biopharmaceutical company incorporated in  focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases such as primary biliary cirrhosis pbc now called primary biliary cholangitis nonalcoholic fatty liver disease or nonalcoholic steatohepatitis nash cirrhosis portal hypertension primary sclerosing cholangitis and also the intestinal disorder bile acid diarrhea productsedit the companys lead product is obeticholic acid oca also known as ethylchenodeoxycholic acid or int marketed as ocaliva oca is a potent firstinclass farnesoid x receptor fxr agonist as of march  ocaliva is approved in the us and the eu for use in primary biliary cholangitis it is in phase iii studies for nonalcoholic steatohepatitis nash and phase ii studies for primary sclerosing cholangitis other products in the development pipeline include int a dual fxrtgr agonist and int a tgr agonist initial public offering and stock historyedit intercept trades on the nasdaq exchange under the ticker symbol icpt the initial public offering of the stock on october   was at  a followon public offering at  took place on june   on january   the stock skyrocketed from  to  or about  after a planned interim analysis by the independent data safety monitoring board showed that obeticholic acid met the main goal improvement of liver histology at the midstage in the flint trial in nash sponsored by niddk the stock continued to climb to  over the next few days before falling back to around  on march   giving a market capitalization of around  billion in march  the company released the results of the poise study of obeticholic acid in pbc which showed the drug met the trials primary endpoint of a reduction in serum alkaline phosphatase a biomarker for the disease these results were presented at an international liver meeting in april  as of  december  the company had  employees referencesedit  intercept pharmaceuticals strong biopharmaceutical ipo seeking alpha october   retrieved    the farnesoid x receptor fxr ligand obeticholic acid in nash treatment trialflint   intercept pharma press release intercept announces nash primary endpoint met flint trial stopped early for efficacy based on highly statistically significant improvement in liver histology retrieved january     intercept pharma press release intercept announces positive pivotal phase  poise trial results retrieved march     intercepts liver disease drug proves highly effective in study reuters april   retrieved april     intercept pharmaceuticals form k annual report  retrieved october    external linksedit intercept pharmaceuticals website  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleinterceptpharmaceuticalsoldid categories companies listed on nasdaqbiotechnology companies of the united statespharmaceutical companies of the united stateshealth care companies based in new yorkhidden categories coordinates not on wikidatapages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view intercept pharmaceuticals  wikipedia intercept pharmaceuticals from wikipedia the free encyclopedia jump to navigation search coordinates °′″n °′″w﻿  ﻿°n °w﻿    intercept pharmaceuticals type public company traded as nasdaq icpt industry biotechnology founded  headquarters new york city new york united states key people mark pruzanski president and ceo jonathan silverstein chairman of the board of directors website wwwinterceptpharmacom intercept pharmaceuticals inc is an american biopharmaceutical company incorporated in  focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases such as primary biliary cirrhosis pbc now called primary biliary cholangitis nonalcoholic fatty liver disease or nonalcoholic steatohepatitis nash cirrhosis portal hypertension primary sclerosing cholangitis and also the intestinal disorder bile acid diarrhea productsedit the companys lead product is obeticholic acid oca also known as ethylchenodeoxycholic acid or int marketed as ocaliva oca is a potent firstinclass farnesoid x receptor fxr agonist as of march  ocaliva is approved in the us and the eu for use in primary biliary cholangitis it is in phase iii studies for nonalcoholic steatohepatitis nash and phase ii studies for primary sclerosing cholangitis other products in the development pipeline include int a dual fxrtgr agonist and int a tgr agonist initial public offering and stock historyedit intercept trades on the nasdaq exchange under the ticker symbol icpt the initial public offering of the stock on october   was at  a followon public offering at  took place on june   on january   the stock skyrocketed from  to  or about  after a planned interim analysis by the independent data safety monitoring board showed that obeticholic acid met the main goal improvement of liver histology at the midstage in the flint trial in nash sponsored by niddk the stock continued to climb to  over the next few days before falling back to around  on march   giving a market capitalization of around  billion in march  the company released the results of the poise study of obeticholic acid in pbc which showed the drug met the trials primary endpoint of a reduction in serum alkaline phosphatase a biomarker for the disease these results were presented at an international liver meeting in april  as of  december  the company had  employees referencesedit  intercept pharmaceuticals strong biopharmaceutical ipo seeking alpha october   retrieved    the farnesoid x receptor fxr ligand obeticholic acid in nash treatment trialflint   intercept pharma press release intercept announces nash primary endpoint met flint trial stopped early for efficacy based on highly statistically significant improvement in liver histology retrieved january     intercept pharma press release intercept announces positive pivotal phase  poise trial results retrieved march     intercepts liver disease drug proves highly effective in study reuters april   retrieved april     intercept pharmaceuticals form k annual report  retrieved october    external linksedit intercept pharmaceuticals website  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleinterceptpharmaceuticalsoldid categories companies listed on nasdaqbiotechnology companies of the united statespharmaceutical companies of the united stateshealth care companies based in new yorkhidden categories coordinates not on wikidatapages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی  語   한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info intercept pharmaceuticals  interceptpharmacom careers partnering toggle navigation about about intercept leadership board of directors contact us rd fxr therapeutic focus pbc nash psc alcoholic hepatitis pipeline expanded access discovery compounds scientific presentations patient resources pbc disease information pbc patient stories investors  media press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage investor faqs contact us about  about intercept leadership board of directors contact us rd  fxr therapeutic areas primary biliary cirrhosis nash portal hypertensioncirrhosis bile acid diarrhea pipeline discovery compounds publications and conference materials patient resources  primary biliary cirrhosis nash investors  press releases events  presentations corporate governance leadership board of directors committee composition contact the board financial information sec filings annual reports quarterly results stock information historic stock lookup investment calculator dividend history analyst coverage ownership profile investor faqs contact us home we are intercept our mission is to build a healthier tomorrow for patients with progressive nonviral liver diseases meet ally ally is a mother teacher and motorcycle enthusiast living with liver disease she is also our inspiration read her story  our medicine visit ocalivacom  clinical trials learn about clinical trials that are currently recruiting see more  news find information about our recent press releases events and presentations see more  website privacy policy privacy shield policy terms of use contact us glossary  hudson yards th floor  new york ny   t icpt   intercept pharmaceuticals inc you are now leaving interceptpharmacom you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents intercept provides this link as a service to its website visitors intercept is not responsible for the content or the privacy policy of any third party websites close this window to return to intercept pharma’s site or click ‘continue’ to proceed  you are now being redirected to intercepts job application site hosted by a third party intercept pharmaceuticals  wikipedia intercept pharmaceuticals from wikipedia the free encyclopedia jump to navigation search coordinates °′″n °′″w﻿  ﻿°n °w﻿    intercept pharmaceuticals type public company traded as nasdaq icpt industry biotechnology founded  headquarters new york city new york united states key people mark pruzanski president and ceo jonathan silverstein chairman of the board of directors website wwwinterceptpharmacom intercept pharmaceuticals inc is an american biopharmaceutical company incorporated in  focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases such as primary biliary cirrhosis pbc now called primary biliary cholangitis nonalcoholic fatty liver disease or nonalcoholic steatohepatitis nash cirrhosis portal hypertension primary sclerosing cholangitis and also the intestinal disorder bile acid diarrhea productsedit the companys lead product is obeticholic acid oca also known as ethylchenodeoxycholic acid or int marketed as ocaliva oca is a potent firstinclass farnesoid x receptor fxr agonist as of march  ocaliva is approved in the us and the eu for use in primary biliary cholangitis it is in phase iii studies for nonalcoholic steatohepatitis nash and phase ii studies for primary sclerosing cholangitis other products in the development pipeline include int a dual fxrtgr agonist and int a tgr agonist initial public offering and stock historyedit intercept trades on the nasdaq exchange under the ticker symbol icpt the initial public offering of the stock on october   was at  a followon public offering at  took place on june   on january   the stock skyrocketed from  to  or about  after a planned interim analysis by the independent data safety monitoring board showed that obeticholic acid met the main goal improvement of liver histology at the midstage in the flint trial in nash sponsored by niddk the stock continued to climb to  over the next few days before falling back to around  on march   giving a market capitalization of around  billion in march  the company released the results of the poise study of obeticholic acid in pbc which showed the drug met the trials primary endpoint of a reduction in serum alkaline phosphatase a biomarker for the disease these results were presented at an international liver meeting in april  as of  december  the company had  employees referencesedit  intercept pharmaceuticals strong biopharmaceutical ipo seeking alpha october   retrieved    the farnesoid x receptor fxr ligand obeticholic acid in nash treatment trialflint   intercept pharma press release intercept announces nash primary endpoint met flint trial stopped early for efficacy based on highly statistically significant improvement in liver histology retrieved january     intercept pharma press release intercept announces positive pivotal phase  poise trial results retrieved march     intercepts liver disease drug proves highly effective in study reuters april   retrieved april     intercept pharmaceuticals form k annual report  retrieved october    external linksedit intercept pharmaceuticals website  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleinterceptpharmaceuticalsoldid categories companies listed on nasdaqbiotechnology companies of the united statespharmaceutical companies of the united stateshealth care companies based in new yorkhidden categories coordinates not on wikidatapages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view intercept pharmaceuticals    facebook facebook？intercept pharmaceuticals非官方主页·：  intercept pharmaceuticals  wikipedia intercept pharmaceuticals from wikipedia the free encyclopedia jump to navigation search coordinates °′″n °′″w﻿  ﻿°n °w﻿    intercept pharmaceuticals type public company traded as nasdaq icpt industry biotechnology founded  headquarters new york city new york united states key people mark pruzanski president and ceo jonathan silverstein chairman of the board of directors website wwwinterceptpharmacom intercept pharmaceuticals inc is an american biopharmaceutical company incorporated in  focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases such as primary biliary cirrhosis pbc now called primary biliary cholangitis nonalcoholic fatty liver disease or nonalcoholic steatohepatitis nash cirrhosis portal hypertension primary sclerosing cholangitis and also the intestinal disorder bile acid diarrhea productsedit the companys lead product is obeticholic acid oca also known as ethylchenodeoxycholic acid or int marketed as ocaliva oca is a potent firstinclass farnesoid x receptor fxr agonist as of march  ocaliva is approved in the us and the eu for use in primary biliary cholangitis it is in phase iii studies for nonalcoholic steatohepatitis nash and phase ii studies for primary sclerosing cholangitis other products in the development pipeline include int a dual fxrtgr agonist and int a tgr agonist initial public offering and stock historyedit intercept trades on the nasdaq exchange under the ticker symbol icpt the initial public offering of the stock on october   was at  a followon public offering at  took place on june   on january   the stock skyrocketed from  to  or about  after a planned interim analysis by the independent data safety monitoring board showed that obeticholic acid met the main goal improvement of liver histology at the midstage in the flint trial in nash sponsored by niddk the stock continued to climb to  over the next few days before falling back to around  on march   giving a market capitalization of around  billion in march  the company released the results of the poise study of obeticholic acid in pbc which showed the drug met the trials primary endpoint of a reduction in serum alkaline phosphatase a biomarker for the disease these results were presented at an international liver meeting in april  as of  december  the company had  employees referencesedit  intercept pharmaceuticals strong biopharmaceutical ipo seeking alpha october   retrieved    the farnesoid x receptor fxr ligand obeticholic acid in nash treatment trialflint   intercept pharma press release intercept announces nash primary endpoint met flint trial stopped early for efficacy based on highly statistically significant improvement in liver histology retrieved january     intercept pharma press release intercept announces positive pivotal phase  poise trial results retrieved march     intercepts liver disease drug proves highly effective in study reuters april   retrieved april     intercept pharmaceuticals form k annual report  retrieved october    external linksedit intercept pharmaceuticals website  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleinterceptpharmaceuticalsoldid categories companies listed on nasdaqbiotechnology companies of the united statespharmaceutical companies of the united stateshealth care companies based in new yorkhidden categories coordinates not on wikidatapages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view